title: Aminothiadiazole (NSC 4728) in patients with advanced nonsquamous carcinoma of the cervix. A phase II study of the Gynecologic Oncology Group.
abstract: Twenty-six evaluable patients with advanced nonsquamous cell cervical cancer were treated with aminothiadiazole at a dosage of 125 mg/m2 weekly. Sixteen had received prior chemotherapy. Two patients had complete responses neither had received prior chemotherapy; nine had stable disease; 15 had increasing disease. There was a single life-threatening toxic episode. Aminothiadiazole used in this dosage and schedule has minimal activity in previously treated patients with nonsquamous cell carcinoma.
authors: Department of Medicine in Oncology, University of Rochester School of Medicine, New York.
authors: R F
authors: RF
authors: Asbury
authors: J A
authors: JA
authors: Blessing
authors: P J
authors: PJ
authors: DiSaia
authors: J
authors: J
authors: Malfetano
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002277:Carcinoma / Q000188:drug therapy*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D011379:Prognosis; D013830:Thiadiazoles / Q000009:adverse effects / Q000627:therapeutic use*; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy*
chemical_list: D000970:Antineoplastic Agents; D013830:Thiadiazoles; C010852:2-amino-1,3,4-thiadiazole